



Dear Colleagues:

We are pleased to inform you N0574, a phase III trial testing the role of whole brain radiotherapy (WBRT) in addition to radiosurgery in patients with one to three brain metastases, continues to accrue well and it is nearing its accrual goal. This trial is of great importance as it is designed to definitively answer whether quality of life and cognitive function is better (or worse) after adjuvant WBRT. As you are likely aware, recently published studies have yielded conflicting results regarding this issue.

In order to answer this essential question we need a total of 56 evaluable (i.e. completed neurocognitive testing at 3 months) patients in each arm. An analysis of the existing data suggests that this testing is missing for several enrolled subjects. We are therefore expanding accrual to address this issue.

Since the 3 month evaluation is so crucial we ask that patients undergo the brief neurocognitive test specified by the trial *even if they are progressing systemically or in the brain at 3 months*. Please remember patients with progressive disease remain on the study as accessing their function over time is just as important as those patients with stable disease.

With your help, we will soon conclude this critical analysis. Again, thank you for your support and if you have any questions, please do not hesitate to contact us.

Sincerely,

Paul Brown, M.D.  
Co-Section Chief CNS/Pediatrics  
Dept. of Radiation Oncology  
UT MD Anderson Cancer Center

Anthony Asher, M.D.  
Director, Brain Tumor Program  
Carolinas Medical Center

Karla Ballman, Ph.D.  
Study Statistician